Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis

Exp Mol Med. 2017 Aug 11;49(8):e365. doi: 10.1038/emm.2017.112.

Abstract

The proteasome inhibitor, bortezomib, is ineffective against many solid tumors. Nutlin-3 is a potent antagonist of human homolog of murine double minute 2/p53 interaction exhibiting promising therapeutic anti-cancer activity. In this study, we show that treatment of various p53-defective bortezomib-resistant solid tumor cells with bortezomib plus nutlin-3 induces paraptosis, which is a cell death mode accompanied by dilation of the endoplasmic reticulum (ER) and mitochondria. Bortezomib alone did not markedly alter cellular morphology, and nutlin-3 alone induced only a transient mitochondrial dilation. However, bortezomib/nutlin-3 co-treatment triggered the progressive fusion of swollen ER and the formation of megamitochondria, leading to cell death. Mechanistically, proteasomal-impairment-induced ER stress, CHOP upregulation and disruption of Ca2+ homeostasis were found to be critically involved in the bortezomib/nutlin-3-induced dilation of the ER. Our results further suggest that mitochondrial unfolded protein stress may play an important role in the mitochondrial dilation observed during bortezomib/nutlin-3-induced cell death. Collectively, these findings suggest that bortezomib/nutlin-3 perturbs proteostasis, triggering ER/mitochondria stress and irrecoverable impairments in their structure and function, ultimately leading to paraptotic cell death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects*
  • Bortezomib / pharmacology*
  • Bortezomib / therapeutic use
  • Calcium / metabolism
  • Dilatation
  • Drug Synergism
  • Endoplasmic Reticulum / metabolism
  • HCT116 Cells
  • HeLa Cells
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • Mitochondria / metabolism
  • Neoplasms / drug therapy*
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors / pharmacology*
  • Proteasome Inhibitors / therapeutic use
  • Transcription Factor CHOP / genetics
  • Transcription Factor CHOP / metabolism
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Antineoplastic Agents
  • DDIT3 protein, human
  • Imidazoles
  • Piperazines
  • Proteasome Inhibitors
  • Tumor Suppressor Protein p53
  • Transcription Factor CHOP
  • nutlin 3
  • Bortezomib
  • Proteasome Endopeptidase Complex
  • Calcium